Fate Therapeutics Inc., of San Diego, was granted U.S. Patent No. 8,044,201, titled "Stem Cell Cultures," which claims Thiazovivin, a small-molecule Rho-associated kinase inhibitor, as well as compositions and cell culture media comprising Thiazovivin.